Graves’ Orbitopathy
A Multidisciplinary Approach – Questions and Answers
Graves’ Orbitopathy

A Multidisciplinary Approach – Questions and Answers

2nd, revised edition

Editors

Wilmar M. Wiersinga  Amsterdam
George J. Kahaly  Mainz

95 figures, 53 in color, and 41 tables, 2010
26 Orbit-Thyroid Relationship  
Lazarus, J.H. (Cardiff); Marino, M. (Pisa)

26 Should This Condition Always Be Called Graves' Orbitopathy?  
26 Does Graves' Orbitopathy Occur in the Absence of Hyperthyroidism?  
28 Do All Patients with Graves' Disease Have Graves' Orbitopathy?  
28 What Comes First in Graves' Disease? The Eye Changes or the Hyperthyroid Symptoms?  
29 Do TSH Receptor Antibodies Also Cause GO?  
30 Are There Any Other Extrathyroidal Manifestations of Graves' Disease Apart from Graves' Orbitopathy?  
31 References

33 Epidemiology  
Daumerie, C. (Brussels)

33 What Is the Present Estimated Prevalence of Graves' Orbitopathy? Has It Changed over the Last Decade?  
34 Is the Age and Sex Distribution of Graves' Orbitopathy Similar to that of Graves' Disease?  
34 Are There Ethnic Differences?  
34 What Are the Risk Factors for the Occurrence of Graves' Orbitopathy?  
35 Is Tobacco Bad for Graves' Orbitopathy?  
36 Is Ocular Co-Morbidity Relevant for Graves' Orbitopathy?  
36 Is Elevated Intraocular Pressure Relevant in Graves' Orbitopathy?  
37 Is There Significant Non-Ocular Co-Morbidity (Like Diabetes) Which Is Relevant for Graves' Orbitopathy?  
38 References

40 Pathogenesis  
Orgiazzi, J. (Pierre-Bénite); Ludgate, M. (Cardiff)

40 What Are the Pathological Changes in Orbital Tissue in Graves' Orbitopathy?  
42 How Do the Pathological Changes Give Rise to the Clinical Manifestations?  
43 What Triggers Graves' Orbitopathy?  
44 Is Graves' Orbitopathy Triggered by an Autoimmune Phenomenon? If So, What Is the Nature of the Autoantigen?  
45 Why Is the Orbit Special and a Target for Thyroid Autoimmunity?  
46 What Kind of Immune Reactions Take Place within the Orbit?  
49 Does TSHR Activation and/or Autoreactivity to TSHR Play a Role in the Onset or Development of Graves' Orbitopathy?  
50 Is There a Familial Predisposition or a Specific Genetic Background for Graves' Orbitopathy?  
51 How Do Environmental Factors such as Smoking Increase the Risk and Severity of Graves' Orbitopathy?  
52 How May These Observations and Current Understanding Lead to More Effective Treatment of Graves' Orbitopathy?  
53 References

57 Orbital Imaging  
Pitz, S. (Mainz)

57 Is Orbital Imaging Always Necessary?  
57 What Are the Relative Benefits of Orbital CT and MRI?  
59 What Is Apical Crowding?
61 What Is the Place of Orbital Ultrasound?
63 What Lessons Can We Learn from Orbital Octreoscan?
63 What Other Imaging Techniques May Be Useful?
64 Acknowledgments
64 References

66 Diagnosis and Differential Diagnosis of Graves’ Orbitopathy
Mourits, M.P. (Amsterdam)
66 Can You Give an Overall Scheme for the Diagnosis of Graves’ Orbitopathy?
66 Which Clinical Findings Are Helpful in Making a Diagnosis of Graves’ Orbitopathy?
70 Can One Make a Diagnosis of Graves’ Orbitopathy Based on Medical History and Clinical Picture Alone?
70 Do We Always Need to Order Thyroid Autoantibodies and Thyroid Function Tests?
71 Which Imaging Technique Is Best to Make a Diagnosis of Graves’ Orbitopathy and Is Imaging Always Requested?
72 Which Are the Most Frequent Conditions Mimicking Graves’ Orbitopathy?
75 Conclusion
75 References

77 Natural History
Pearce, S.; Kendall-Taylor, P. (Newcastle upon Tyne)
77 Does Graves’ Orbitopathy Occur at the Same Time as Hyperthyroidism?
78 Does Restoring Euthyroidism Lead to Improvement in Graves’ Orbitopathy?
79 What Effect May Hypothyroidism Have?
79 What Is the Typical Course of the Disease?
80 What Is the Difference between Activity and Severity?
82 How Do You Determine which Phase of the Disease the Patient Is Displaying?
83 How Does the Phase of the Disease Influence Choice of Treatment?
83 Will the GO Eventually Burn Itself Out?
84 Will the Orbital Changes Return to Normal when the Condition Eventually Resolves?
84 How Long Is it Likely to Take before the Disease Becomes Inactive?
84 Once the Condition Has Become Inactive (Whether Treated or Untreated) Is it Likely to Flare Up Again?
85 Are There Any Other Factors, Additional to Thyroid Status, which May Influence the Course of the Disease?
86 References

88 General Management Plan
Boboridis, K. (Thessaloniki); Perros, P. (Newcastle upon Tyne)
88 Is There General Agreement among Specialists on How to Manage GO?
88 What Are the Priorities when Faced with a New Presentation of Graves’ Orbitopathy?
89 How Good Is the Evidence that Quitting Smoking Helps?
89 Does Thyroid Status Affect the Eyes?
90 What Simple Measures Can Help the Eyes?
91 Is There a Place for Botulinum Toxin?
92 How Do You Define Mild, Moderately Severe, and Very Severe Graves’ Orbitopathy?
92 Can You Give a Simplified Overall Management Scheme?
94 References
96 Combined Thyroid-Eye Clinics
Wiersinga, W.M. (Amsterdam)

96 What Are Combined Thyroid-Eye Clinics?
97 Why Is a Multidisciplinary Approach Recommended?
98 Can Patient-Support Groups Be Helpful?
98 I Have Heard of a Fast-Track Clinic for Graves’ Orbitopathy Patients: What Is That?
99 References

100 Thyroid Treatment
Marcocci, C.; Pinchera, A. (Pisa)

100 Does It Matter for the Eyes How the Patient Is Rendered Euthyroid?
103 Are There Any Specific Criteria to Prefer One of the Treatment Modalities for Hyperthyroidism in Graves’ Orbitopathy?
104 Is There Any Risk Factor Which May Predict Appearance or Worsening of Graves’ Orbitopathy after Radioiodine?
105 Should the Presence of Graves’ Orbitopathy Limit the Use of Radioiodine Therapy?
107 Does Transient Hypothyroidism following Therapy Influence the Course of Graves’ Orbitopathy?
107 Has Total Thyroid Ablation a Role in the Management of Hyperthyroidism in Graves’ Orbitopathy?
109 References

111 Management of Mild Graves’ Orbitopathy
Salvi, M.; Currò, N. (Milan)

111 What Is the Degree of Intra-Orbital Involvement in Mild Graves’ Orbitopathy?
111 Are Mild Forms of Graves’ Orbitopathy Likely to Progress to More Severe Graves’ Orbitopathy?
112 Is a ‘Wait and See’ Policy Justified in Mild Graves’ Orbitopathy?
114 Are Low-Dosage Oral Steroids Advisable or Is Orbital Irradiation Preferable?
115 Can We Reassure Patients about the Long-Term Safety of Orbital Irradiation?
116 What Is the Rationale for Antioxidant Therapy in GO?
117 References

120 Management of Moderately Severe Graves’ Orbitopathy
Kahaly, G.J. (Mainz)

120 Is There a New Definition of Moderately Severe Graves’ Orbitopathy?
120 Is Immunosuppression Indicated in Moderately Severe Graves’ Orbitopathy?
121 What Are the Results of Randomized Trials with Steroids?
121 What Are the Results of Randomized Trials Using Orbital Radiotherapy?
128 Do You Favor Combined Steroid/Radiotherapy?
139 What Are the Results of Randomized Trials Using Non-steroid Immunosuppressants?
148 What Is Rituximab and Is It a Useful Therapeutic Tool in Moderately Severe GO?
149 What Are the Results of Randomized Trials Using Somatostatin Analogs?
151 How Should a Diabetic or Hypertensive Patient with Moderately Severe GO Be Treated?
152 What Should You do if Steroids Fail?
153 What are the Current Evidence-Based Therapeutic Recommendations for Patients with Moderately Severe GO?
154 What Are the Overall Recommendations of the Recently Published EUGOGO Consensus Statement for the Management of Moderately Severe GO?
154 Acknowledgments
155 References
Management of Very Severe Graves' Orbitopathy (Dysthyroid Optic Neuropathy and Corneal Breakdown)
Lane, C.M. (Cardiff); Boschi, A. (Brussels)

1. How Do You Define Dysthyroid Optic Neuropathy?
2. Are There Specific Risk Factors for Dysthyroid Optic Neuropathy?
3. Which Symptoms Should Alert Me?
4. What Are the Ophthalmological Signs of Dysthyroid Optic Neuropathy?
5. Are Additional Investigations Helpful?
6. How Fast Can Dysthyroid Optic Neuropathy Develop? Is Urgent Treatment Necessary?
7. What Is the Evidence Base for the Treatment of Dysthyroid Optic Neuropathy?
8. What Is the Role of Surgery in Dysthyroid Optic Neuropathy?
9. How Many Patients Become Blind due to Dysthyroid Optic Neuropathy?
10. How Can I Recognize Corneal Breakdown?
11. What Is the Recommended Treatment of Corneal Breakdown?

Rehabilitative Surgery
Baldeschi, L. (Amsterdam)

1. Why Is This Chapter Called Rehabilitative Surgery and Not Cosmetic Surgery?
2. What Are the Steps and Timing of Rehabilitative Surgery?
3. How Should Patients Be Selected for Rehabilitative Surgery?

Orbital Decompression
Baldeschi, L. (Amsterdam)

1. What Is Orbital Decompression?
2. What Are the Aims of Orbital Decompression?
3. Which Surgical Technique Should Be Preferred?
4. What Are the Possible Complications of Orbital Decompression?
5. Can Complications Be Predicted or Prevented?

Eye Muscle Surgery
Nardi, M. (Pisa)

1. What Is the Cause of Ocular Motility Impairment?
2. How Do You Identify the Affected Muscles?
3. How Can You Avoid Diagnostic Errors in Complex Cases?
4. How Can You Evaluate the Need for Surgery?
5. When Is the Right Time for Surgery?
6. What Can You Realistically Expect from Surgery?
7. How Should You Advise the Patient?
8. The Surgical Plan: What Procedures Are Recommended?
9. What Are the Possible Complications of Surgery and How Can I Avoid or Manage Them?

Eyelid Surgery
Neoh, C. (Newcastle upon Tyne); Eckstein, A. (Essen)

1. What Are the Indications for Eyelid Surgery in Patients with Graves' Orbitopathy?
2. Is Botulinum Toxin Useful?
202 Is Surgical Intervention Indicated in Corneal Ulceration Secondary to Exposure Keratopathy?
203 Does Orbital Decompression Have Any Effect on Lid Retraction?
203 Does Squint Surgery Influence the Lid Configuration?
204 What Surgical Procedures Are Available for Correction of Upper Lid Retraction?
207 Are There Complications?
207 What Surgical Procedures Are Available for Correction of Lower Lid Retraction?
207 Should This Be Combined with Horizontal Lid Tightening?
208 Which Materials Are Suitable for Use as Spacers? Should the Use of Allogeneic Grafts Be Avoided?
209 Are There Complications?
209 What about Upper Lid Debulking and Upper and Lower Lid Blepharoplasty?
207 References

Miscellaneous Issues

211 Quality of Life
Wiersinga, W.M. (Amsterdam)
211 What Is Quality of Life?
211 What Is the Usefulness of Quality of Life Measurements?
213 What Is Known about General Health-Related Quality of Life in Graves’ Orbitopathy?
214 Is There a GO-Specific Quality of Life Questionnaire?
216 What Are the Results of the GO-QoL?
216 Can You Explain Response Shift in Quality of Life?
217 Can GO-QoL Be Used as a Separate Outcome Measurement in GO?
218 Is Quality of Life Fully Restored after Treatment of GO?
219 Can I Apply the GO-QoL in My Own Practice?
219 References

221 Socioeconomic Impact
Kahaly, G.J. (Mainz)
221 Is There an Actual Cost Estimation of Thyroid Disorders in Germany and/or Europe?
222 Does Graves’ Orbitopathy Lead to Occupational Disability?
222 How Were Data Obtained on Occupational Disability and Impaired Earning Capacity in Graves’ Orbitopathy?
223 What Are the Findings of the Prospective Study?
225 How Should We Interpret the Data Obtained on Occupational Disability and Impaired Earning Capacity in Patients with GO?
225 What Are the Relevant Implications for Daily Clinical Practice?
226 Acknowledgment
226 References

228 Atypical Manifestations
von Arx, G. (Olten)
228 What Are the Atypical Manifestations of Graves’ Orbitopathy?
228 How Do You Explain Unilateral Graves’ Orbitopathy (We Don’t Have Graves’ Hyperthyroidism in Just One Thyroid Lobe, Do We?)
232 Will Unilateral Graves’ Orbitopathy Proceed to Bilateral Graves’ Orbitopathy?
233 Is the Clinical Presentation of Unilateral Graves’ Orbitopathy Different from Bilateral Graves’ Orbitopathy?
234 How Does Unilaterality Affect Treatment?
235 Is Euthyroid Graves’ Orbitopathy a Reason to Refrain from Specific Eye Treatment?
239 **Childhood Graves’ Orbitopathy**  
Krasas, G.E. (Thessaloniki)

239 Is Childhood Graves’ Orbitopathy Really That Rare?
241 Is the Clinical Presentation of Graves’ Orbitopathy in Childhood Different from that in Adulthood?
242 Why Is Graves’ Orbitopathy in Children Less Severe than in Adults?
243 What Is the Best Therapeutic Approach for Graves’ Orbitopathy in Children and Adolescents?
245 What about Surgical Decompression of the Orbit in Childhood?

248 **Prevention**  
Bartalena, L. (Varese)

248 What Is Primary, Secondary and Tertiary Prevention?
248 Can a General Strategy Be Applied to Prevent Graves’ Orbitopathy?
249 What Can Be Done in the Primary Prevention of Graves’ Orbitopathy?
250 What Can Be Done in Terms of Secondary Prevention of Graves’ Orbitopathy?
252 What about Tertiary Prevention of Graves’ Orbitopathy?
252 What Should One Do when Talking to a Graves’ Orbitopathy Patient Who Smokes?

253 **Future Developments**  
Salvi, M. (Milan); Baldeschi, L. (Amsterdam)

255 Is There Evidence that Steroids in Graves’ Orbitopathy Act as True Immunosuppressants and Modify Disease Outcome?
256 What Are the Reasons for Exploring the Potential Efficacy of New Immunosuppressive Medications?
256 Is There Evidence for the Efficacy of New Immunotherapy Agents in Graves’ Orbitopathy?
257 Which Anticytokine Treatment Would Be the Most Effective in Your Opinion?
258 What About Rituximab?
258 What about Interfering with the TSH Receptor Pathways?
260 Are Technical Developments in Surgical Approaches to Be Expected?
261 Are Conceptual Developments in Surgical Approaches to Be Expected?

265 **The Amsterdam Declaration on Graves’ Orbitopathy**  
Perros, P. (Newcastle upon Tyne)

265 Why Is There a Need for a Declaration on Graves’ Orbitopathy?
265 Why Is the Declaration Called the Amsterdam Declaration?
266 What Is the Text of the Amsterdam Declaration?
266 Who Signed the Amsterdam Declaration?
266 Can Other Societies Still Sign the Declaration?

270 References
271 Historical Notes on Graves' Disease
Mourits, M.P. (Amsterdam)

271 Is It Fair to Call Graves' Disease 'Graves' Disease'?
272 Various Eye Signs Carry Specific Names: Are They Still Relevant?
272 How Did Old Theories Explain the Relationship between Hyperthyroidism and Proptosis?
274 What Are Rundle's Contributions to Our Understanding of Graves' Orbitopathy?
276 What Are Kriss' Contributions to the Management of Graves' Orbitopathy?
278 When Was Evidence-Based Medicine Incorporated in Graves' Orbitopathy?
278 References

280 Author Index
281 Subject Index
Preface to the Second, Revised Edition

The first edition of *Graves’ Orbitopathy: A Multidisciplinary Approach* was very well received. We are grateful for the many pieces of positive feedback and constructive comments from our readers. The multidisciplinary approach and the question-and-answer format appears to be a highly successful formula, warranting a second edition of the book within 3 years of the first.

All chapters have been thoroughly updated, and it is gratifying to see how much progress has been made not only in better understanding the pathogenesis of Graves’ orbitopathy, but also in its treatment. The EUGOGO consensus statement on management of Graves’ orbitopathy has been accepted worldwide as a useful guideline, and is now fully incorporated in the text. Two new chapters have been added: one describing the socioeconomic impact of the disease and the other outlining the Amsterdam Declaration on Graves’ Orbitopathy. This declaration, aiming to improve outcomes for thyroid eye disease, was signed by 82 national and international organizations in the field of thyroidology and ophthalmology at the International Symposium on Graves’ Orbitopathy held in October 2010 in Amsterdam on the occasion of the 10th anniversary of EUGOGO.

We hope the 2nd edition will again contribute to improvements in the quality of care delivered by health professionals to patients with Graves’ orbitopathy.

On behalf of EUGOGO,
Wilmar M. Wiersinga, Editor
George J. Kahaly, Co-Editor
Amsterdam and Mainz, June 2010
Preface to the First Edition

We are very pleased to present *Graves’ Orbitopathy: A Multidisciplinary Approach*.

The title of the book is a reflection of our opinion that real progress can be made in understanding thyroid eye disease and in improving outcome of the disfiguring and often invalidating eye changes associated with Graves’ orbitopathy only if specialists of various disciplines work closely together. In other words, we favour a multidisciplinary approach in which internists/endocrinologists, ophthalmologists/orbital surgeons and basic scientists combine their forces. This has been the philosophy since the foundation of EUGOGO, the European Group on Graves’ Orbitopathy in 1999. The group is currently composed of 13 centres in 8 European countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Switzerland and the United Kingdom), and, in accordance with our philosophy, each centre is represented by specialists in internal medicine and ophthalmology. A further requirement of EUGOGO membership is that each participating centre must have combined thyroid-eye clinics in which the patient can be seen simultaneously by physicians from both disciplines. It is gratifying to note that the number of combined thyroid-eye clinics has been increasing slowly but steadily throughout Europe over the last decade, thereby enhancing the quality of patient care.

EUGOGO meets twice a year, and we have had many lengthy and at times heated discussions on how to assess the eye changes in a most objective manner and what the best treatment should be. It has taken us several years to reach an acceptable degree of agreement among ourselves, again illustrating the many pitfalls in the management of Graves’ orbitopathy as well as the importance of using a multidisciplinary approach. Only then could we embark on prospective clinical trials (the size of the group allows completion of clinical studies in a much shorter time than possible for each individual centre), on teaching courses how to investigate and treat the patient with Graves’ orbitopathy (so far three courses have been held – Thessalonica 2005, Pisa 2006, and Mainz 2007), and on papers in scientific journals describing the outcome of our studies and recommendations on disease management.

The present book reflects our current thinking on Graves’ orbitopathy: all authors are EUGOGO members. The internal consistency between chapters is the result of our ongoing discussions during the annual EUGOGO meetings. The outline of the
book is unusual by its choosing the question-and-answer format. The purpose is to enable the book to also be used as a quick reference source for the practicing physician confronted with an ordinary or extraordinary management question: most likely the answer can be found in one of the 194 questions asked in this book. We do not apologise for some overlap between chapters (especially on smoking and thyroid treatment), because these issues are relevant to many aspects of Graves’ orbitopathy and it facilitates fast retrieval of the information you are looking for. Topics such as unilateral eye disease, childhood Graves’ orbitopathy, and disease-specific quality-of-life assessment which are not easily found elsewhere receive the attention they deserve. The editors welcome feedback from the readership: please send your comments to us; also on how future editions could be improved. You may also consult the EUGOGO website (www.eugogo.eu).

We would like to thank the patients with Graves’ orbitopathy who cooperated in our endeavours to better understand their disease. We also thank S. Karger AG, Medical and Scientific Publishers, for their efforts to edit, produce, and publish the book within a very short time. Last but not least, we are grateful to the authors for their excellent contributions. It again proves how much can be accomplished by a group of dedicated people.

Wilmar M. Wiersinga, President EUGOGO, Editor
George J. Kahaly, Treasurer EUGOGO, Co-Editor
Amsterdam and Mainz, June 2007